Search

Your search keyword '"Baiocchi, Robert A,"' showing total 945 results
Start Over Author "Baiocchi, Robert A,"
945 results on '"Baiocchi, Robert A,"'

201. Efficacy and Safety of ATA129, Partially Matched Allogeneic Third-Party Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes in a Multicenter Study for Post-Transplant Lymphoproliferative Disorder

Author

Prockop, Susan E., primary, Li, Ai, additional, Baiocchi, Robert, additional, Bunin, Nancy J., additional, Mahadeo, Kris Michael, additional, Nemecek, Eneida R., additional, Nikiforow, Sarah, additional, Reshef, Ran, additional, Tsai, Donald Edward, additional, Navarro, Willis H., additional, and O'Reilly, Richard J., additional

Published
2018
Full Text
View/download PDF

202. PRMT5 as a druggable target for glioblastoma therapy

Author

Banasavadi-Siddegowda, Yeshavanth Kumar, primary, Welker, Alessandra M, additional, An, Min, additional, Yang, Xiaozhi, additional, Zhou, Wei, additional, Shi, Guqin, additional, Imitola, Jaime, additional, Li, Chenglong, additional, Hsu, Sigmund, additional, Wang, Jiang, additional, Phelps, Mitch, additional, Zhang, Jianying, additional, Beattie, Christine E, additional, Baiocchi, Robert, additional, and Kaur, Balveen, additional

Published
2017
Full Text
View/download PDF

204. A phase 1b/pharmacokinetic trial of PTC299, a novel post-transcriptional VEGF inhibitor, for AIDS-related Kaposi’s sarcoma: AIDS Malignancy Consortium trial 059

Author

Aboulafia, David, Tulpule, Anil, Dezube, Bruce J., Dittmer, Dirk P., Ignacio, Rachel A. Bender, Chavakula, Veenadhari, Mitsuyasu, Ronald T., Rudek, Michelle A., Sparano, Joseph A., Ambinder, Richard F., Lynne, Julia, Krown, Susan E., Chiao, Elizabeth Y., Reid, Erin Gourley, Baiocchi, Robert, Lee, Jeannette Y., Eason, Anthony, and Shiramizu, Bruce

Abstract

Vascular endothelial growth factor (VEGF) plays an important role in Kaposi’s sarcoma (KS). We administered PTC299, a post-transcriptional inhibitor of pathogenic VEGF, to persons with HIV-related KS. Seventeen participants received three different doses of PTC299. Adverse events typically observed with VEGF-inhibition were absent. Three participants had partial tumor responses and 11 had stable disease. There were no differences in exposure to PTC299 by antiretroviral regimen. Serum VEGF, but not KSHV DNA, decreased on treatment. Given redundancies in the VEGF feedback loop, future trials should consider combining PTC299 with agents that inhibit different pathways implicated in KS and KSHV proliferation.

Published
2016
Full Text
View/download PDF

205. Correction: PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis

Author

Webb, Lindsay M., primary, Amici, Stephanie A., additional, Jablonski, Kyle A., additional, Savardekar, Himanshu, additional, Panfil, Amanda R., additional, Li, Linsen, additional, Zhou, Wei, additional, Peine, Kevin, additional, Karkhanis, Vrajesh, additional, Bachelder, Eric M., additional, Ainslie, Kristy M., additional, Green, Patrick L., additional, Li, Chenglong, additional, Baiocchi, Robert A., additional, and Guerau-de-Arellano, Mireia, additional

Published
2017
Full Text
View/download PDF

206. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib

Author

Wiczer, Tracy E., primary, Levine, Lauren B., additional, Brumbaugh, Jessica, additional, Coggins, Jessica, additional, Zhao, Qiuhong, additional, Ruppert, Amy S., additional, Rogers, Kerry, additional, McCoy, Anli, additional, Mousa, Luay, additional, Guha, Avirup, additional, Heerema, Nyla A., additional, Maddocks, Kami, additional, Christian, Beth, additional, Andritsos, Leslie A., additional, Jaglowski, Samantha, additional, Devine, Steven, additional, Baiocchi, Robert, additional, Woyach, Jennifer, additional, Jones, Jeffrey, additional, Grever, Michael, additional, Blum, Kristie A., additional, Byrd, John C., additional, and Awan, Farrukh T., additional

Published
2017
Full Text
View/download PDF

208. Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma

Author

Jaime-Ramirez, Alena C., primary, Yu, Jun-Ge, additional, Caserta, Enrico, additional, Yoo, Ji Young, additional, Zhang, Jianying, additional, Lee, Tae Jin, additional, Hofmeister, Craig, additional, Lee, John H., additional, Kumar, Bhavna, additional, Pan, Quintin, additional, Kumar, Pawan, additional, Baiocchi, Robert, additional, Teknos, Theodoros, additional, Pichiorri, Flavia, additional, Kaur, Balveen, additional, and Old, Matthew, additional

Published
2017
Full Text
View/download PDF

210. A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas

Author

Sborov, Douglas W., primary, Canella, Alessandro, additional, Hade, Erinn M., additional, Mo, Xiaokui, additional, Khountham, Soun, additional, Wang, Jiang, additional, Ni, Wenjun, additional, Poi, Ming, additional, Coss, Christopher, additional, Liu, Zhongfa, additional, Phelps, Mitch A., additional, Mortazavi, Amir, additional, Andritsos, Leslie, additional, Baiocchi, Robert A., additional, Christian, Beth A., additional, Benson, Don M., additional, Flynn, Joseph, additional, Porcu, Pierluigi, additional, Byrd, John C., additional, Pichiorri, Flavia, additional, and Hofmeister, Craig C., additional

Published
2017
Full Text
View/download PDF

212. PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis

Author

Webb, Lindsay M., primary, Amici, Stephanie A., additional, Jablonski, Kyle A., additional, Savardekar, Himanshu, additional, Panfil, Amanda R., additional, Li, Linsen, additional, Zhou, Wei, additional, Peine, Kevin, additional, Karkhanis, Vrajesh, additional, Bachelder, Eric M., additional, Ainslie, Kristy M., additional, Green, Patrick L., additional, Li, Chenglong, additional, Baiocchi, Robert A., additional, and Guerau-de-Arellano, Mireia, additional

Published
2017
Full Text
View/download PDF

213. Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status

Author

Kumar, Bhavna, primary, Yadav, Arti, additional, Brown, Nicole V., additional, Zhao, Songzhu, additional, Cipolla, Michael J., additional, Wakely, Paul E., additional, Schmitt, Alessandra C., additional, Baiocchi, Robert A., additional, Teknos, Theodoros N., additional, Old, Matthew, additional, and Kumar, Pawan, additional

Published
2017
Full Text
View/download PDF

215. PRMT5 Transgenic Mice Develop Aggressive Lymphoblastic Lymphomas

Author

Smith, Porsha L., primary, Yan, Fengting, additional, Patton, John T., additional, Alinari, Lapo, additional, Karkhanis, Vrajesh, additional, Ayers, Leona, additional, Muthusamy, Natarajan, additional, Mishra, Anjali, additional, Ahmed, Elshafa, additional, Sif, Said, additional, Lapalombella, Rosa, additional, and Baiocchi, Robert A, additional

Published
2016
Full Text
View/download PDF

217. Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial

Author

Makowski, Mat, primary, Ahmed, Elshafa, additional, Schlotter, Sarah, additional, Pearson, Rebecca, additional, Kitzler, Rhonda, additional, Alvarnas, Joseph C., additional, Le Rademacher, Jennifer, additional, Wang, Yanli, additional, Little, Richard F, additional, Akpek, Gorgun, additional, Ayala, Ernesto, additional, Devine, Steven M., additional, Kaplan, Lawrence D., additional, Noy, Ariela, additional, Popat, Uday R., additional, Hsu, Jack W, additional, Morris, Lawrence E., additional, Thompson, Jason, additional, Horowitz, Mary H, additional, Mendizabal, Adam M., additional, Levine, Alexandra M., additional, Krishnan, Amrita, additional, Hade, Erinn, additional, Hofmeister, Craig C, additional, Forman, Stephen J., additional, Navarro, Willis H., additional, Ambinder, Richard F., additional, Lozanski, Gerard, additional, and Baiocchi, Robert A, additional

Published
2016
Full Text
View/download PDF

220. The Epstein-Barr virus lytic protein BZLF1 as a candidate target antigen for vaccine development1

Author

Hartlage, Alex S., Liu, Tom, Patton, John T., Garman, Sabrina L., Zhang, Xiaoli, Kurt, Habibe, Lozanski, Gerard, Lustberg, Mark E., Caligiuri, Michael A., and Baiocchi, Robert A.

Subjects
Herpesvirus 4, Human, Immunity, Cellular, Mice, viruses, hemic and lymphatic diseases, Trans-Activators, Vaccines, DNA, Animals, Humans, Mice, SCID, biochemical phenomena, metabolism, and nutrition, CD8-Positive T-Lymphocytes, Article
Abstract

The Epstein-Barr virus (EBV) is an oncogenic, γ-herpesvirus associated with a broad spectrum of disease. Although most immune-competent individuals can effectivley develop efficient adaptive immune responses to EBV, immunocompromised individuals are at serious risk for developing life-threatening diseases, such as Hodgkin lymphoma and posttransplant lymphoproliferative disorder (PTLD). Given the significant morbidity associated with EBV infection in high-risk populations, there is a need to develop vaccine strategies that restore or enhance EBV-specific immune responses. Here, we identify the EBV immediate-early protein BZLF1 as a potential target antigen for vaccine development. Primary tumors from patients with PTLD and a chimeric human-murine model of EBV-driven lymphoproliferative disorder (EBV-LPD) express BZLF1 protein. Pulsing human dendritic cells (DC) with recombinant BZLF1 followed by incubation with autologous mononuclear cells led to expansion of BZLF1-specific CD8(+) T cells in vitro and primed BZLF1-specific T-cell responses in vivo. In addition, vaccination of hu-PBL-SCID mice with BZLF1-transduced DCs induced specific cellular immunity and significantly prolonged survival from fatal EBV-LPD. These findings identify BZLF1 as a candidate target protein in the immunosurveillance of EBV and provide a rationale for considering BZLF1 in vaccine strategies to enhance primary and recall immune responses and potentially prevent EBV-associated diseases.

Published
2015

221. PU.1 and epigenetic signals modulate 1,25‐dihydroxyvitamin D3 and C/EBPα regulation of the human cathelicidin antimicrobial peptide gene in lung epithelial cells.

Author

Wei, Ran, Dhawan, Puneet, Baiocchi, Robert A., Kim, Ki‐Yoon, and Christakos, Sylvia

Subjects
CATHELICIDINS, CHROMATIN-remodeling complexes, EPITHELIAL cells
Abstract

LL‐37, the only known human cathelicidin which is encoded by the human antimicrobial peptide (CAMP) gene, plays a critical role in protection against bacterial infection. We previously demonstrated that cathelicidin is induced by 1,25‐dihydroxyvitamin D3 (1,25(OH) 2D 3) in human airway epithelial cells with a resultant increase in bactericidal activity. In this study we identify key factors that co‐operate with 1,25(OH) 2D 3 in the regulation of CAMP. Our results show for the first time that PU.1, the myeloid transcription factor (which has also been identified in lung epithelial cells), co‐operates with the vitamin D receptor and CCAAT/enhancer binding protein α (CEBPα) to enhance the induction of CAMP in lung epithelial cells. Our findings also indicate that enhancement of 1,25(OH) 2D 3 regulation of CAMP by histone deacetylase inhibitors involves co‐operation between acetylation and chromatin remodeling through Brahma‐related gene 1 (BRG1; a component of the SWItch/sucrose nonfermentable [SWI/SNF] complex). BRG1 can be an activator or repressor depending on BRG1‐associated factors. Protein arginine methyltransferase 5 (PRMT5), a methlytransferase which interacts with BRG1, represses 1,25(OH) 2D 3 induced CAMP in part through dimethylation of H4R3. Our findings identify key mediators involved in the regulation of the CAMP gene in lung epithelial cells and suggest new approaches for therapeutic manipulation of gene expression to increase the antibacterial capability of the airway. This study shows for the first time that PU.1 co‐operates with the vitamin D receptor and CCAAT/enhancer binding protein α (CEBPα) to enhance the induction of cathelicidin antimicrobial peptide (CAMP) in lung epithelial cells. It also indicates that enhancement of 1,25(OH)2D3 regulation of CAMP by histone deacetylase inhibitors involves co‐operation between acetylation and chromatin remodeling through Brahma‐related gene 1 (BRG1). Protein arginine methyltransferase 5 (PRMT5) interacts with BRG1 and represses 1,25(OH)2D3 induced CAMP in part through dimethylation of H4R3. Our findings identify key mediators involved in the regulation of the CAMP gene in lung epithelial cells and suggest new approaches for therapeutic manipulation of gene expression to increase the antibacterial capability of the airway. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

222. Postinfusion PD-1+CD8+CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma

Author

Denlinger, Nathan, Song, No-Joon, Zhang, Xiaoli, Jeon, Hyeongseon, Peterson, Chelsea, Wang, Yi, Reynolds, Kelsi, Bolz, Robert M., Miao, Jessica, Song, Chunhua, Wu, Dayong, Chan, Wing Keung, Bezerra, Evandro, Epperla, Narendranath, Voorhees, Timothy J., Brammer, Jonathan, Kittai, Adam S., Bond, David A., Sawalha, Yazeed, Sigmund, Audrey, Reneau, John C., Rubinstein, Mark P., Hanel, Walter, Christian, Beth, Baiocchi, Robert A., Maddocks, Kami, Alinari, Lapo, Vasu, Sumithira, de Lima, Marcos, Chung, Dongjun, Jaglowski, Samantha, Li, Zihai, Huang, Xiaopei, and Yang, Yiping

Abstract

•After CAR T-cell infusion, circulating PD-1+CAR+CD8+T cells are highly associated with response to CAR T-cell therapy for NHL.•Spectral flow analysis reveals specific populations of stem-like and effector-like CAR T cells, which correlate with improved outcomes.

Published
2024
Full Text
View/download PDF

223. Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses

Author

Briercheck, Edward L., Ravishankar, Shashidhar, Ahmed, Elshafa Hassan, Carías Alvarado, César Camilo, Barrios Menéndez, Juan Carlos, Silva, Oscar, Solórzano-Ortiz, Elizabeth, Siliézar Tala, Marcos Mauricio, Stevenson, Philip, Xu, Yuexin, Wohns, Anthony Wilder, Enriquez-Vera, Daniel, Barrionuevo, Carlos, Yu, Shan-Chi, Freud, Aharon G., Oakes, Christopher, Weigel, Christoph, Weinstock, David M., Klimaszewski, Haley L., Ngankeu, Apollinaire, Mutalima, Nora, Samayoa-Reyes, Gabriela, Newton, Robert, Rochford, Rosemary, Valvert, Fabiola, Natkunam, Yasodha, Shustov, Andrei, Baiocchi, Robert A., and Warren, Edus H.

Abstract

•Geography, rather than disease, has a greater influence on genome-wide EBV variation.•Variation in EBV genomes predicts altered viral peptide binding to major histocompatibility complex, necessitating tailored vaccine and cellular therapy strategies.

Published
2024
Full Text
View/download PDF

224. Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial

Author

Sawalha, Yazeed, Welkie, Rina Li, Krivenko, Anna, Hess, Brian, Sigmund, Audrey M., Voorhees, Timothy, Hanel, Walter, Bond, David A., Reneau, John C, Epperla, Narendranath, Alinari, Lapo, Brammer, Jonathan E., Christian, Beth, Baiocchi, Robert, and Maddocks, Kami J.

Abstract

Introduction. Although most patients (pts) with DLBCL are cured with R-CHOP, ~40% develop refractory or relapsed disease. Several studies have shown a potential therapeutic role for BTK inhibitors in DLBCL. In the phase 3 PHOENIX trial of pts with DLBCL, the addition of ibrutinib to R-CHOP failed to improve overall outcomes. However, in pts <60 years, ibrutinib plus R-CHOP improved the progression-free (PFS) and overall (OS) survivals. The age-based difference in outcomes with ibrutinib plus R-CHOP may be due to greater toxicity and reduced R-CHOP dose intensity with this combination in older pts. We hypothesized that zanubrutinib, a 2 nd-generation BTK inhibitor with greater selectivity for BTK and improved safety compared with ibrutinib, could be safely combined with R-CHOP and improve outcomes.

Published
2023
Full Text
View/download PDF

225. Targeting EBV Encoded Viral Kinases with GCV, AZT, Rituximab and Dexamethasone (GARD) Results in Durable Responses in Patients with CNS Lymphoproliferative Disease

Author

Klimaszewski, Haley L., Weigel, Christoph, Addissie, Selamawit, Schlotter, Sarah, Fode, Tounkara, Dugan, James P., Haverkos, Bradley M., Villagomez, Lynda, Lustberg, Mark, Porcu, Pierluigi, Voorhees, Timothy, Caligiuri, Michael A, Oakes, Christopher C., Bumgardner, Ginny, and Baiocchi, Robert

Abstract

Introduction: Epstein-Barr virus positive (EBV+) central nervous system lymphoproliferative diseases (CNS-LPD) are aggressive clinical conditions with poor prognosis. EBV+ CNS-LPD often occurs in the setting of immune suppression and comorbidities (solid organ transplant, autoimmunity). Treatment with high-dose methotrexate has increased survival but is not a viable option for all patients, highlighting the need for alternative treatments. Previous research has reported EBV+ CNS-LPD exhibits unique genetic and immunobiological signatures, however, few studies have reported on the epigenetic landscape. We have previously reported use of ganciclovir (GCV), zidovudine (AZT), rituximab and dexamethasone (GARD) regimen induced complete and durable responses in a cohort of 13 patients with primary CNS post-transplant lymphoproliferative disease (PCNS-PTLD). Here we present 24 patients (10 from prior cohort and 14 new) with EBV+ CNS-LPD treated with GARD. We extend follow-up time for the previous cohort and add molecular context to clinical observations. We performed DNA methylation and expression analysis of EBV viral kinases in available tumor samples and revealed unique viral epigenetic states leading to expression of antiviral drug targets in an array of EBV+ CNS-LPD.

Published
2023
Full Text
View/download PDF

226. Differences in Observed Toxicities for Adolescent and Young Adult Patients with Aggressive Mature B-Cell Lymphomas Treated at Adult Versus Pediatric Cancer Center - a Comparative Cohort Study

Author

Lehanka, Allison M, Kebede, Ann, Amirmokhtari, Neda, Stanek, Joseph R, Epperla, Narendranath, Christian, Beth, Baiocchi, Robert, Voorhees, Timothy, Maddocks, Kami J., Sawalha, Yazeed, Reneau, John C, Brammer, Jonathan E., Sigmund, Audrey M., Willen, Faye, Yeager, Nick, Audino, Anthony N., and Bond, David A.

Abstract

Introduction: Standard treatment regimens for pediatric and adult patients with mature B-cell lymphomas vary significantly. For adolescent or young adult (AYA) patients, who may be candidates for either pediatric or adult regimens, limited data are available regarding comparative toxicities and efficacy for adult versus pediatric therapies.

Published
2023
Full Text
View/download PDF

227. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases

Author

Haverkos, Bradley M., primary, Pan, Zenggang, additional, Gru, Alejandro A., additional, Freud, Aharon G., additional, Rabinovitch, Rachel, additional, Xu-Welliver, Meng, additional, Otto, Brad, additional, Barrionuevo, Carlos, additional, Baiocchi, Robert A., additional, Rochford, Rosemary, additional, and Porcu, Pierluigi, additional

Published
2016
Full Text
View/download PDF

228. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial

Author

Alvarnas, Joseph C., primary, Le Rademacher, Jennifer, additional, Wang, Yanli, additional, Little, Richard F., additional, Akpek, Gorgun, additional, Ayala, Ernesto, additional, Devine, Steven, additional, Baiocchi, Robert, additional, Lozanski, Gerard, additional, Kaplan, Lawrence, additional, Noy, Ariela, additional, Popat, Uday, additional, Hsu, Jack, additional, Morris, Lawrence E., additional, Thompson, Jason, additional, Horowitz, Mary M., additional, Mendizabal, Adam, additional, Levine, Alexandra, additional, Krishnan, Amrita, additional, Forman, Stephen J., additional, Navarro, Willis H., additional, and Ambinder, Richard, additional

Published
2016
Full Text
View/download PDF

229. Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma

Author

Haverkos, Bradley M., primary, Gru, Alejandro A., additional, Geyer, Susan M., additional, Bingman, Anissa K., additional, Hemminger, Jessica A., additional, Mishra, Anjali, additional, Wong, Henry K., additional, Pancholi, Preeti, additional, Freud, Aharon G., additional, Caligiuri, Michael A., additional, Baiocchi, Robert A., additional, and Porcu, Pierluigi, additional

Published
2016
Full Text
View/download PDF

231. NKp80 Defines a Critical Step during Human Natural Killer Cell Development

Author

Freud, Aharon G., primary, Keller, Karen A., additional, Scoville, Steven D., additional, Mundy-Bosse, Bethany L., additional, Cheng, Stephanie, additional, Youssef, Youssef, additional, Hughes, Tiffany, additional, Zhang, Xiaoli, additional, Mo, Xiaokui, additional, Porcu, Pierluigi, additional, Baiocchi, Robert A., additional, Yu, Jianhua, additional, Carson, William E., additional, and Caligiuri, Michael A., additional

Published
2016
Full Text
View/download PDF

232. A phase 1 trial of vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced stage head and neck squamous cell carcinoma.

Author

Teknos, Theodoros Nicholas, primary, Old, Matthew Owen, additional, Grecula, John C., additional, Agrawal, Amit, additional, Ozer, Enver, additional, Carrau, Ricardo, additional, Kang, Stephan, additional, Rocco, James William, additional, Blakaj, Dukagjin, additional, Diavolitsis, Virginia, additional, Baiocchi, Robert A., additional, Kumar, Bhavna, additional, and Savvides, Panayiotis, additional

Published
2016
Full Text
View/download PDF

233. Epigenetic modulation of inflammatory T cell responses

Author

Webb, Lindsay M, primary, Savardekar, Himanshu, additional, Jablonski, Kyle, additional, Amici, Stephanie A, additional, Panfil, Amanda, additional, Smith, Porsha, additional, Green, Patrick, additional, Li, Chenglong, additional, Baiocchi, Robert A, additional, and Guerau-De-Arellano, Mireia, additional

Published
2016
Full Text
View/download PDF

234. Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma

Author

Stiff, Andrew, primary, Caserta, Enrico, additional, Sborov, Douglas W., additional, Nuovo, Gerard J., additional, Mo, Xiaokui, additional, Schlotter, Sarah Y., additional, Canella, Alessandro, additional, Smith, Emily, additional, Badway, Joseph, additional, Old, Matthew, additional, Jaime-Ramirez, Alena Cristina, additional, Yan, Pearlly, additional, Benson, Don M., additional, Byrd, John C., additional, Baiocchi, Robert, additional, Kaur, Balveen, additional, Hofmeister, Craig C., additional, and Pichiorri, Flavia, additional

Published
2016
Full Text
View/download PDF

238. Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium

Author

Noy, Ariela, primary, Lensing, Shelly Y., additional, Moore, Page C., additional, Gupta, Neel, additional, Aboulafia, David, additional, Ambinder, Richard, additional, Baiocchi, Robert, additional, Dezube, Bruce J, additional, Henry, David, additional, Kaplan, Lawrence, additional, Levine, Alexandra M., additional, Mitsuyasu, Ronald, additional, Ratner, Lee, additional, Reid, Erin, additional, Remick, Scot, additional, Sparano, Joseph, additional, Tzachanis, Dimitrios, additional, Wachsman, William, additional, and Chadburn, Amy, additional

Published
2015
Full Text
View/download PDF

243. Update on Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Author

Shindiapina, Polina, Pietrzak, Maciej, Seweryn, Michal, McLaughlin, Eric, Zhang, Xiaoli, Makowski, Mat, Ahmed, Elshafa, Pearson, Rebecca, Kitzler, Rhonda, Le-Rademacher, Jennifer G., Little, Richard F, Akpek, Görgün, Ayala, Ernesto, Devine, Steven M., Kaplan, Lawrence D., Noy, Ariela, Popat, Uday R., Hsu, Jack W., Morris, Lawrence E, Mendizabal, Adam, Wachsman, William, Williams, Nita, Sharma, Nidhi, Hofmeister, Craig C, Forman, Stephen J., Navarro, Willis H., Alvarnas, Joseph C., Ambinder, Richard F., Malvestutto, Carlos, Choe, Hannah, Behbehani, Gregory, Lozanski, Gerard, Blaser, Bradley, and Baiocchi, Robert

Published
2023
Full Text
View/download PDF

244. New and Updated Results from a Multicenter, Open-Label, Global Phase 3 (P3) Study of Tabelecleucel (Tab-cel) for Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab (R) or Rituximab and Chemotherapy (R+CT) (ALLELE)

Author

Beitinjaneh, Amer, Baiocchi, Robert, Chaganti, Sridhar, Choquet, Sylvain, Dierickx, Daan, Dinavahi, Rajani, Gamelin, Laurence, Ghobadi, Armin, Guzman-Becerra, Norma, Joshi, AJ, Mahadeo, Kris Michael, Mehta, Dr. Aditi, Nikiforow, Sarah, Reshef, Ran, Ye, Wei, and Prockop, Susan

Published
2023
Full Text
View/download PDF

245. PRMT5 as a druggable target for glioblastoma therapy.

Author

Banasavadi-Siddegowda, Yeshavanth Kumar, Welker, Alessandra M., Min An, Xiaozhi Yang, Wei Zhou, Guqin Shi, Imitola, Jaime, Chenglong Li, Hsu, Sigmund, Jiang Wang, Phelps, Mitch, Jianying Zhang, Beattie, Christine E., Baiocchi, Robert, and Kaur, Balveen

Published
2018
Full Text
View/download PDF

246. Synthesis, biological evaluation, and radioiodination of halogenated closo-carboranyl thymidine analogues1

Author

Tiwari, Rohit, Toppino, Antonio, Agarwal, Hitesh K., Huo, Tianyao, Byun, Youngjoo, Gallucci, Judith, Hasabelnaby, Sherifa, Khalil, Ahmed, Goudah, Ayman, Baiocchi, Robert A., Darby, Michael V., Barth, Rolf. F., and Tjarks, Werner

Subjects
Iodine Radioisotopes, Models, Molecular, Mice, Halogenation, Animals, Humans, Phosphorylation, Crystallography, X-Ray, Thymidine Kinase, Article, Cell Line, Protein Binding, Thymidine
Abstract

The synthesis and initial biological evaluation of 3-carboranylthymidine analogues (3CTAs) that are (radio)halogenated at the closo-carborane cluster are described. Radiohalogenated 3CTAs have the potential to be used in the radiotherapy and imaging of cancer because they may be selectively entrapped in tumor cells through monophosphorylation by human thymidine kinase 1 (hTK1). Two strategies for the synthesis of a (127)I-labeled form of a specific 3CTA, previously designated as N5, are described: (1) direct iodination of N5 with iodine monochloride and aluminum chloride to obtain N5-(127)I and (2) initial monoiodination of o-carborane to 9-iodo-o-carborane followed by its functionalization to N5-(127)I. The former strategy produced N5-(127)I in low yields along with di-, tri-, and tetraiodinated N5 as well as decomposition products, whereas the latter method produced only N5-(127)I in high yields. N5-(127)I was subjected to nucleophilic halogen- and isotope-exchange reactions using Na(79/81)Br and Na(125)I, respectively, in the presence of Herrmann's catalyst to obtain N5-(79/81)Br and N5-(125)I, respectively. Two intermediate products formed using the second strategy, 1-(tert-butyldimethylsilyl)-9-iodo-o-carborane and 1-(tert-butyldimethylsilyl)-12-iodo-o-carborane, were subjected to X-ray diffraction studies to confirm that substitution at a single carbon atom of 9-iodo-o-carborane resulted in the formation of two structural isomers. To the best of our knowledge, this is the first report of halogen- and isotope-exchange reactions of B-halocarboranes that have been conjugated to a complex biomolecule. Human TK1 phosphorylation rates of N5, N5-(127)I, and N5-(79/81)Br ranged from 38.0% to 29.6% relative to that of thymidine, the endogenous hTK1 substrate. The in vitro uptake of N5, N5-(127)I, and N5-(79/81)Br in L929 TK1(+) cells was 2.0, 1.8, and 1.4 times greater than that in L929 TK1(-) cells.

Published
2011

248. Malignant NK Cells from EBV(+) Human Extranodal NK/T Cell Lymphoma Exhibit Features of a Distinct NK Cell Developmental Subset Found in Mucosal Associated Lymphoid Tissue

Author

Mishra, Anjali, Mundy-Bosse, Bethany L, Young, Karen A, Weigel, Christoph, Smith, Emily, Elshafa, Ahmed, Youssef, Youssef, McConnell, Kathleen, Plass, Christoph, Brammer, Jonathan E, Baiocchi, Robert A, Caligiuri, Michael A., Porcu, Pierluigi, Freud, Aharon G., and Oakes, Christopher C.

Published
2017
Full Text
View/download PDF

249. Phase II trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma

Author

Baiocchi, Robert A., Alinari, Lapo, Lustberg, Mark E., Lin, Thomas S., Porcu, Pierluigi, Li, Xiaobai, Johnston, Jeffrey S., Byrd, John C., and Blum, Kristie A.

Subjects
Adult, Male, Drug Evaluation, Preclinical, Antineoplastic Agents, Lymphoma, Mantle-Cell, Polymorphism, Single Nucleotide, Article, Bortezomib, Antibodies, Monoclonal, Murine-Derived, Mice, Recurrence, Antineoplastic Combined Chemotherapy Protocols, Animals, Humans, Lymphoma, Follicular, Aged, Neoplasm Staging, Aged, 80 and over, Receptors, IgG, Middle Aged, Boronic Acids, Disease Models, Animal, Treatment Outcome, Pyrazines, Female, Rituximab, Proteasome Inhibitors
Abstract

In vitro studies in mantle cell lymphoma (MCL) cell lines and patient-derived cells have demonstrated synergistic apoptosis with combined rituximab and bortezomib (R-bortezomib) compared with single-agent bortezomib. Therefore, the authors of this report evaluated R-bortezomib in a preclinical model and in a phase 2 clinical trial.A Hu-MCL-severe combined immunodeficiency (SCID) model engrafted with the Jeko cell line was treated with R-bortezomib, bortezomib, or rituximab. Twenty-five patients with relapsed follicular lymphoma (n = 11) and MCL (n = 14) received 375 mg/m(2) rituximab on Days 1 and 8 and 1.3 to 1.5 mg/m(2) bortezomib on Days 1, 4, 8, and 11 every 21 days for a median of 3 cycles (range, 1-5 cycles).R-bortezomib resulted in a statistically significant improvement in overall survival in Hu-MCL-SCID mice. In the clinical trial, the overall response rate was 40% in all 25 patients, 55% in patients with follicular lymphoma, and 29% in patients with MCL. The estimated 2-year progression-free survival (PFS) rate was 24% (95% confidence interval [CI], 10%-53%) in all patients and 60% (95% CI, 20%-85%) in responding patients. Thirteen patients (52%) developed grade 3 neurotoxicity, which consisted of constipation/ileus, sensory or motor neuropathy, or orthostatic hypotension. Patients who were heterozygous for the CD32a (Fcγ receptor IIa) 131 histidine (H) to arginine (R) polymorphism had a significantly decreased PFS (P = .009) after R-bortezomib compared with HH and RR homozygotes.R-bortezomib had significant activity in patients with relapsed or refractory follicular lymphoma and MCL, although an unexpectedly high incidence of grade 3 neurologic toxicity was a potential limiting factor with this combination.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results